RECURSION PHARMACEUTICALS-A (RXRX)
US75629V1044 - Common Stock
RECURSION PHARMACEUTICALS-A
NASDAQ:RXRX (5/17/2024, 7:24:40 PM)
After market: 9.33 -0.09 (-0.96%)9.42
-0.09 (-0.95%)
Company Profile
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah and currently employs 500 full-time employees. The company went IPO on 2021-04-16. The company is focused on utilizing advanced technologies in biology, chemistry, automation, and computer science to discover and design therapeutics. The Company’s platform, Recursion Operating System (OS), is built with diverse technologies and enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The company integrates physical and digital components as iterative loops of atoms and bits of wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is an orally bioavailable, superoxide, scavenger small molecule being developed for the treatment of cerebral cavernous malformation (CCM). REC-2282 is developed for the treatment of neurofibromatosis type 2.
Company Info
RECURSION PHARMACEUTICALS-A
41S Rio Grande Street
Salt Lake City UTAH 84101
P: 13852690203
CEO: Christopher Gibson
Employees: 500
Website: https://www.recursion.com/
RXRX News
3 days ago - The Motley FoolWhat's the Difference Between Biotech Stocks and TechBio Stocks?A few enterprising businesses are marketing themselves differently.
A few enterprising businesses are marketing themselves differently.
4 days ago - Investor's Business DailyRecursion Pharm Stock Sees Relative Strength Rating Rise To 84On Tuesday, Recursion Pharm stock had its Relative Strength (RS) Rating upgraded to 84, up from 78 a day earlier.
5 days ago - Recursion PharmaceuticalsRecursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical IndustryBioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024.
BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all...
6 days ago - The Motley FoolCathie Wood Is Buying This Under-the-Radar AI StockThis company has massive upside potential, but that's not the whole story.
RXRX Twits
Here you can normally see the latest stock twits on RXRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
